Previous Close | 0.1000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 17.50 |
Expire Date | 2024-06-21 |
Day's Range | 0.1000 - 0.2000 |
Contract Range | N/A |
Volume | |
Open Interest | 1.13k |
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe diseaseSingle dose of NTLA-2002 led to a 98% mean reduction in monthly HAE attack rate, with an average follow-up of over 20 months across a
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) just released its quarterly report and things are looking bullish. Results...